Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib plus Apatinib vs Chemotherapy in HRD+/HER2- Advanced Breast Cancer
NCT06255392Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2024
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluzoparib, Rivoceranib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Jun 2024; status: recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06255392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255392.